CHF10067 for Idiopathic Pulmonary Fibrosis

(ZAPPHIRE Trial)

This trial tests a new treatment called CHF10067, or zampilimab, for individuals with idiopathic pulmonary fibrosis (IPF), a lung disease that makes breathing difficult. Researchers aim to assess the treatment's effectiveness and safety after 24 weeks. Participants will be divided into three groups: two groups will receive different doses of the treatment, and one group will receive a placebo (a substance with no active drug). Individuals with a confirmed IPF diagnosis for up to 8 years and who experience breathing difficulties might be suitable candidates. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

Previous studies showed that zampilimab, also known as CHF10067, was well tolerated by participants. No deaths or serious side effects led to treatment discontinuation. Participants did not experience major problems from using zampilimab. Notably, these studies tested various doses, and no major safety issues emerged at any level. This suggests that zampilimab is generally safe for use.¹²³⁴⁵

Most treatments for idiopathic pulmonary fibrosis, like pirfenidone and nintedanib, aim to slow down lung scarring but don't significantly improve lung function. Zampilimab (CHF10067) is different because it targets an innovative pathway that could potentially reduce inflammation and fibrosis more effectively. Researchers are excited because this new mechanism might not only slow disease progression but also improve patients' lung function and quality of life, offering hope beyond the current standard of care.

This trial will evaluate CHF10067 (Zampilimab) for idiopathic pulmonary fibrosis (IPF). Participants will join different arms, including two experimental arms with varying doses of Zampilimab and a placebo comparator arm. Studies have shown that Zampilimab can significantly improve lung function in people with IPF. Specifically, early results suggest that this treatment enhances lung performance and improves certain lung test results after 24 weeks. Research indicates that Zampilimab targets the lung scarring process, crucial for managing IPF. Overall, these early findings offer promise for those facing this challenging condition.¹³⁴⁶⁷